Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer.

ABSTRACT: OBJECTIVE:To identify the optimal adjuvant treatment regimen for patients with endometrioid and non-endometrioid node-positive endometrial cancer. METHODS:We retrospectively identified 249 women with FIGO 2009 stage IIIC endometrial cancer at our institution who underwent surgical staging from 1985 to 2015 followed by external beam radiotherapy (RT), chemotherapy (CT), or a combination of CT?+?RT. Survival rates were calculated using the Kaplan-Meier method. RESULTS:The 5-year disease-specific survival (DSS) rate for all patients was 65%. Adjuvant CT?+?RT conferred higher rates of 5-year DSS as compared to CT alone in patients with grade 3 endometrioid and non-endometrioid tumors (61% vs. 27%, P?=?0.04 and 67% vs. 38%, P?=?0.02, respectively). Among patients with non-endometrioid tumors, treatment with concurrent chemoradiotherapy followed by additional sequential chemotherapy had higher 5-year DSS rates than with concurrent chemoradiotherapy alone (74% vs. 50%, P?=?0.02). The 3-year pelvic recurrence rate was 5% with RT?±?CT and 35% with CT alone (P?

SUBMITTER: Chapman BV 

PROVIDER: S-EPMC7523189 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature